At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 119 enrolled
Drug / intervention
Obicetrapib +3 moredrug
Likely dose
Ezetimibe 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study
In Brief
A Phase 2 clinical trial evaluating Obicetrapib, Ezetimibe 10mg, and 2 other interventions for Dyslipidemias and 2 related conditions. Completed, enrolled 119 participants across 16 sites.
Detailed Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, High Cholesterol, Hypercholesterolemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMar 2022
Primary CompletionAug 2022
Study CompletionSep 2022
TodayJul 2026
First PostedMar 4, 2022
Enrollment StartMar 9, 2022
Primary CompletionAug 12, 2022
Study CompletionSep 8, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.3 years ago
Interventions
Obicetrapibdrug
tablets
Ezetimibe 10mgdrug
capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
Obicetrapib placeboother
tablets; no active ingredient
Ezetimibe placeboother
capsules; no active ingredient